P256 - ECE_2728 - Impact of setmelanotide on metabolic index scores in Phase 3 trial participants with acquired hypothalamic obesity
Acquired hypothalamic obesity (aHO) is a rare complex disease characterized by hyperphagia and reduced energy expenditure, leading to accelerated and sustained weight gain. Commonly associated with pituitary hormone deficiencies, fatigue, or sleep disturbances, aHO puts patients at high risk for metabolic complic...